ADMT TO SUBMIT POWERFUL DRUG FREE PAIN TREATMENT FOR FAST TRACK 51O(k) TO FDA

• After over a decade of R&D and remarkable successes in treating pain fast and effectively, ADM Tronics is now commercially launching the Vet Sonotron for the drug-free treatment of pain in animals.  See video of injured horse in pain to the touch and remarkable pain treatment that worked with no drugs in just a few minutes.

• The United States Veterinary Services market accounted for USD 21.83 billion in 2022 and is expected to surpass USD 47.92 Billion by 2035 and the only known effective pain treatment is drugs that have adverse effects.

• ADMT is now ready to begin to preparing a fast track 510(k) submission to the FDA for the same effective drug-free treatment of pain for humans.

• The Vet Sonotron is highly effective at reducing pain and inflammation in animals and has also demonstrated similar impressive efficacy in human trials.

• Both products are well positioned for rapid adoption by the markets for animals and humans where the need for effective drug-free pain treatment is unmet.

• ADMT shares closed at $.075 on April 19, 2024, and support a market cap of about $5 million.  The company has no toxic debt.

 

ADM Tronics (ADMT: OTCQB) recently presented their breakthrough pain treatment device, the Vet Sonotron, to 350,000 member MDG Medical Device Group.  The presentation provided an in-depth exploration of the development, testing, and outstanding efficacy of the Vet-Sonotron in treating musculoskeletal pain conditions in small animals, including dogs as well as horses.

​

View the webinar here: https://tinyurl.com/yb28txjk

​

The Vet-Sonotron represents a significant advancement in veterinary care, offering a non-invasive solution for managing pain and promoting healing in animals. Developed and tested over the past several years, this cutting-edge device utilizes proprietary non-invasive therapeutic technology to deliver targeted therapy with excellent results.  "We are proud to introduce the Vet-Sonotron to the medical device community through this webinar," said Mr. DiMino, the CEO of ADM Tronics. "This device has significant potential in the way pain management is approached in small animals and in horses, providing veterinarians with a powerful tool to improve the quality of life for their patients."

​

The webinar included an overview of the testing conducted to assess the efficacy of the Vet-Sonotron. Results demonstrated the device's ability to significantly reduce pain and inflammation, accelerate healing, and improve mobility in dogs and horses suffering from both acute and chronic musculoskeletal conditions.

​

The webinar was hosted by Joe Hage, Chair of MDG Premium and leader of the Medical Devices Group (medicaldevicesgroup.net), with over 350,000 members in the medical device and related industries.  Attendees of the webinar, members of MDG Premium, including medical device professionals, researchers, and industry experts, had the opportunity to engage with Mr. DiMino during a Q&A session following the presentation. The lively discussion delved into various aspects of the Vet-Sonotron technology, its applications, and the future development of a human medical version of the technology.

​

Early clinical results have also demonstrated remarkable efficacy of the Drug Free Sonotron when used to treat humans. Now that the Sonotron is actually in production and beginning marketing and sales, ADM Tronics, a proven medical device expert ,with long track record of successful submissions with the FDA, is planning on submitting a fast track 510(k) with the FDA for use for humans where the need for drug free pain relief is very large and unmet.

​

Conclusion

If the Sonotron continues to perform as it has in the past, and if the FDA approves the fast track 510(k), then it could become a high-profile new treatment in the large market for humans as well as for animals.  With a total market cap of close to $5 million, if the Sonotron is adopted by the veterinary market for animals, the increase in valuation could be dramatic, but if also adopted for human use, the increase could be magnitudes higher.  Investors are encouraged to investigate regulatory filings and understand any risks that can potentially impact their investment as well as any event that can potentially increase valuations.

​

For more information about the Vet-Sonotron and contract medical device development and manufacturing services by ADM Tronics, visit www.admtronics.com.

​

Investor Relations:

Howard Isaacs 562-987-4939 HISAACS@EARTHLINK.NET

Richard Cavalli 303-956-1777 RICHARDACAVALLI@GMAIL.COM

​

Legal Disclosures and Disclaimers

Green Planet Microcaps is not a registered investment adviser. The information that we provide from our website or newsletters is not, and should not be construed in any manner, to be investment advice. All opinions and information provided on this site are for educational and research purposes. Green Planet Microcaps encourages all readers to do their own due diligence and research when determining which investment strategies are best suited for them or to seek the advice of an investment professional.

​

Any information provided by Green Planet Microcaps should not be construed by any subscriber or prospective subscriber as a solicitation by Green Planet Microcaps to effect, or attempt to effect, any transaction in any security. Investments in the securities markets, and especially in private securities of small start-up companies, are incredibly and highly speculative and involve substantial risk that your entire investment could be lost. The information that we provide or that is derived from our website and/or newsletters should not be a substitute for advice from an investment professional. We encourage you to obtain personal advice from your professional investment advisor and to make independent investigations before acting on the information that you obtain from Green Planet Microcaps or derive from our website and/or newsletters. Only you can determine what level of risk is appropriate for you.

​

Specifically, we advise all readers and subscribers to seek advice from a registered professional securities representative before deciding to purchase or trade in stocks or any securities presented on this website and/or in a particular newsletter. All information provided regarding the companies featured comes from the companies themselves, SEC filings, news releases, private placement memoranda, company websites as well as other sources of publicly available information. The profiles of these highlighted public and private companies are not in any way a solicitation or recommendation to buy, sell, or hold these or any other securities.

​

Most of the information on our website and/or newsletters or that we otherwise provide is derived directly from information published by the companies on which we report and/or from other sources we believe are reliable, without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. The information may contain discussions of, or provide access to, certain positions and recommendations as of a specific date. Due to various factors, including, but not limited to, changing market conditions, such discussions and positions/recommendations may no longer be reflective of current discussions and positions/recommendations. We do not in any way warrant or guarantee the success of nor endorse any action which you take in reliance on the information that we provide or that is derived from our website.

​

Investors should not rely solely on the information contained on this website or in any specific newsletter. Rather, investors should use the information contained on this Website and/or in newsletters as a starting point for doing additional independent research on the featured private and public companies. The advertisements within this newsletter are not to be construed as offers to purchase securities in the companies which may be the subject of such advertisements pursuant to federal or state law or the laws of any foreign jurisdiction.

Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as “projects”, “foresee”, “expects’”, “will,” “anticipates,” “estimates,” “believes,” “understands” or that by statements indicating certain actions “may,” “could,” or “might” occur. There is no guarantee past performance will be indicative of future results. The accuracy or completeness of the information in this newsletter is only as reliable as the sources they were obtained from.​ Green Planet Microcaps was compensated for this article this month and will not be liable for any consequential, incidental, punitive, special, exemplary or indirect damages resulting directly or indirectly from the use of or reliance upon any material provided by Green Planet Microcaps or derived from Green Planet Microcap’s website and/or newsletters. Green Planet Microcaps shall not be responsible or liable for any loss or damages related to, either directly or indirectly, (1) any decline in market value or loss of any investment; (2) a subscriber’s inability to use or any delay in accessing Green Planet Microcaps website or any other source of material provided by Green Planet Microcaps including newsletters; (3) any absence of material on Green Planet Microcaps; (4) Green Planet Microcaps failure to deliver or delay in delivering any material or (5) any kind of error in transmission of material. Green Planet Microcaps and each subscriber acknowledge that, without limitation, the above-enumerated conditions cannot be the probable result of any breach of any agreement between Green Planet Microcaps and the subscriber.

​

Green Planet Microcaps is not affiliated with any brokerage firm and does not endorse or recommend any specific brokerage firm. Green Planet Microcaps is not and will not be responsible for any trades made by a broker on the subscriber’s behalf under any circumstances.